Results 21 to 30 of about 728 (161)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study [PDF]

Frontiers in Pharmacology, 2023
Objectives: Aficamten is a selective, small-molecule allosteric inhibitor of cardiac sarcomere being developed as a chronic oral treatment for patients with symptomatic obstructive hypertrophic cardiomyopathy.
Xue Zhao, Hongzhong Liu, Wei Tian, Ligang Fang, Mengyang Yu, Xiaofei Wu, Aijing Liu, Ruijie Wan, Li Li, Jinghui Luo, Yuqiong Li, Bo Liu, Yu He, Xiaowen Chen, Yuan Li, Donghong Xu, Hongyun Wang, Xiaohong Han   +17 more
doaj   +5 more sources

Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten. [PDF]

Clin Pharmacokinet
Aficamten, a small-molecule, selective cardiac myosin inhibitor, is under development for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Xu D, Lutz JD, Divanji P, Li J, Benattia Y, Griffith A, Heitner SB, Kupfer S, German P.   +8 more
europepmc   +4 more sources

Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. [PDF]

Eur Heart J
Background and Aims Patients with obstructive hypertrophic cardiomyopathy (oHCM) treated with aficamten in SEQUOIA-HCM (NCT05186818) demonstrated marked improvement in symptoms and functional capacity.
Maron MS, Gimeno JR, Veselka J, Barriales-Villa R, Claggett BL, Coats CJ, Hegde SM, Januzzi JL, Kulac IJ, Masri A, Nassif ME, Spertus JA, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Olivotto I.   +17 more
europepmc   +5 more sources

Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials [PDF]

Open Heart
Background Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes.
Ayesha Aman, Arfa Akram, Bisma Akram, Momina Maham, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Furqan Yaqub   +7 more
doaj   +3 more sources

Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges [PDF]

Biomolecules
Hypertrophic cardiomyopathy (HCM) is a prevalent and often underdiagnosed genetic cardiac disorder characterized by left ventricular hypertrophy and, in many cases, dynamic left ventricular outflow tract obstruction (LVOTO).
Arnold Kukowka, Marek Droździk
doaj   +2 more sources

Myosin Modulator Aficamten Inhibits Force by Altering Myosin’s Biochemical Activity Without Changing Thick Filament Structure [PDF]

JACC: Basic to Translational Science
Summary: We investigated the effects of aficamten on cardiac muscle structure, biochemical activity, and contractile function. Aficamten does not structurally sequester myosin heads along the thick filament.
Saffie Mohran, PhD, Kristina B. Kooiker, PhD, Ateeqa Naim, BS, Matvey Pilagov, BS, Anthony Asencio, BS, Kyrah L. Turner, BS, Weikang Ma, PhD, Galina Flint, MD., Siyao Jiang, BS, Jing Zhao, BS, Timothy S. McMillen, PhD, Christian Mandrycky, PhD, Max Mahoney-Schaefer, BS, Thomas C. Irving, PhD, Bertrand C.W. Tanner, PhD, Neil M. Kad, PhD, Michael Regnier, PhD, Farid Moussavi-Harami, MD   +17 more
doaj   +2 more sources

Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy [PDF]

Reviews in Cardiovascular Medicine
Hypertrophic cardiomyopathy (HCM) represents the most common inherited cardiac disease and a leading cause of heart failure, arrhythmias, and sudden cardiac death in young individuals.
Farbod Sedaghat-Hamedani, Elham Kayvanpour, Benjamin Meder   +2 more
doaj   +2 more sources

Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics.

JACC: Heart Failure
Beta-blockers and nondihydropyridine calcium-channel blockers have been standard-of-care (SOC) medications for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), even though these agents do not directly affect the underlying ...
P. García-Pavía, Ozlem Bilen, Melissa Burroughs, J. Costabel, Edileide de Barros Correia, A. Dybro, P. Elliott, N. Lakdawala, Amy Mann, Ajith Nair, M. Nassif, S. Poulsen, P. Reant, P. C. Schulze, Andrew Wang, I. Berhane, S. Heitner, D. Jacoby, S. Kupfer, F. Malik, L. Meng, R. Sohn, A. Wohltman, M. Fifer   +23 more
semanticscholar   +2 more sources

Effect of Cardiac Myosin Inhibitors on Echocardiographic Features of Cardiac Structure and Function in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis [PDF]

Reviews in Cardiovascular Medicine
Background: Recent advancements have introduced novel cardiac myosin inhibitors (CMIs) that have demonstrated significant efficacy in treating hypertrophic cardiomyopathy (HCM).
Yang Lu, Yuanyuan Zhu, Zhuang Tian
doaj   +2 more sources

Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM [PDF]

Journal of Education, Health and Sport
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak   +3 more
doaj   +3 more sources